Rigel director granted 5,750 RSUs

Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost.

Rhea-AI Filing Summary

Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.

Insider Trade Summary

Grant/Award: 5,750 shares

Grant/Award 1 txn

Insider Frohlich Mark W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,750	$0.00	$0.00

Holdings After Transaction: Common Stock — 7,000 shares (Direct)

Footnotes (1)

1. F1. The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Key Figures

RSU grant size: 5,750 units Grant price: $0.00 per share Shares owned after grant: 7,000 shares

3 metrics

RSU grant size 5,750 units Restricted stock units of common stock granted to director

Grant price $0.00 per share Equity award granted as compensation, not purchased for cash

Shares owned after grant 7,000 shares Total common stock beneficially owned following the award

Key Terms

Restricted Stock Unit, Annual Meeting, Board of Directors

3 terms

Restricted Stock Unit financial

"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Annual Meeting financial

"The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

Board of Directors financial

"subject to the Reporting Person's continuous service on the Company's Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rigel Pharmaceuticals (RIGL) disclose about Mark W. Frohlich in this Form 4?

Rigel Pharmaceuticals reported that director Mark W. Frohlich received 5,750 restricted stock units of common stock as an equity award. These units vest in full before the next annual meeting, increasing his beneficial ownership to 7,000 shares, all held directly.

How many Rigel (RIGL) shares did Mark W. Frohlich acquire in this transaction?

The Form 4 shows Mark W. Frohlich was granted 5,750 restricted stock units of Rigel common stock. The award is structured as equity compensation and will convert into shares upon vesting rather than through a cash purchase in the open market.

At what price were the Rigel (RIGL) shares granted to Mark W. Frohlich?

The reported transaction price per share is $0.00 because the 5,750 units are a restricted stock unit award. As compensation, they are not purchased for cash but vest into common shares if service-based conditions on Rigel’s board are satisfied.

When will Mark W. Frohlich’s 5,750 Rigel (RIGL) RSUs vest?

The restricted stock units are scheduled to fully vest on the date prior to Rigel Pharmaceuticals’ next annual meeting. Vesting is conditioned on Frohlich’s continuous service on the company’s board of directors through that time, according to the Form 4 footnote.

What is Mark W. Frohlich’s total Rigel (RIGL) shareholding after this Form 4 transaction?

After the reported award, Mark W. Frohlich beneficially owns 7,000 shares of Rigel common stock. This figure reflects his direct holdings following the grant of 5,750 restricted stock units that will convert to shares upon vesting, assuming service conditions are met.

Is Mark W. Frohlich’s Rigel (RIGL) transaction a market buy or a compensation grant?

The transaction is a compensation grant, not a market purchase. The Form 4 uses code “A” and notes 5,750 restricted stock units awarded at $0.00 per share, to be acquired upon vesting rather than through an open-market buy or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 08:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frohlich Mark W

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		A		5,750(1)	A	$0	7,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

	/s/ Raymond Furey (Attorney-in-Fact)	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)